BeOne Medicines (ONC) Competitors

BeOne Medicines (NASDAQ:ONC) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

Do insiders and institutionals hold more shares of ONC or GSK?

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 6.6% of BeOne Medicines shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Do analysts prefer ONC or GSK?

BeOne Medicines currently has a consensus target price of $320.67, suggesting a potential upside of 32.95%. GSK has a consensus target price of $37.38, suggesting a potential downside of 3.04%. Given BeOne Medicines' stronger consensus rating and higher probable upside, equities analysts clearly believe BeOne Medicines is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
GSK	1 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.10

Is ONC or GSK more profitable?

GSK has a net margin of 9.89% compared to BeOne Medicines' net margin of -9.40%. GSK's return on equity of 48.82% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	-9.40%	-7.55%	-4.42%
GSK	9.89%	48.82%	11.15%

Which has higher valuation and earnings, ONC or GSK?

GSK has higher revenue and earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$3.81B	6.94	-$644.79M	-$3.72	-64.84
GSK	$40.10B	1.97	$3.29B	$1.94	19.87

Does the media refer more to ONC or GSK?

In the previous week, BeOne Medicines had 5 more articles in the media than GSK. MarketBeat recorded 23 mentions for BeOne Medicines and 18 mentions for GSK. BeOne Medicines' average media sentiment score of 0.38 beat GSK's score of 0.36 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
GSK	8 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk and volatility, ONC or GSK?

BeOne Medicines has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.

Summary

GSK beats BeOne Medicines on 10 of the 17 factors compared between the two stocks.